 |
BioWorld-International-2006-06-14
Novartis Remaining Busy, Buying NeuTec For £305M
Novartis, Intercell Form Deal Worth Up To €67M
No Abstract
BioWorld International Correspondent
Intercell AG entered a marketing and distribution agreement with Novartis AG under which the latter company will sell its Japanese encephalitis virus (JEV) vaccine, IC51, in the U.S., Europe, Japan, Latin America and other selected territories.
Novartis Remaining Busy, Buying NeuTec For £305M
LONDON - Another UK antibody company was swept up, as Novartis AG sealed a recommended all-cash offer worth £305.1 million (US$569 million) for NeuTec Pharma plc, paying more than twice the Manchester-based company's market capitalization. (BioWorld International)